Oxford halts AstraZeneca trials in children and adolescents pending safety data. Another hit for the AstraZeneca vaccine . The fears and reluctance about its safety after the cases of thrombi detected in vaccinated have reached the University of Oxford -developer, together with the pharmacist, of the British vaccine-, which has decided to pause the trials that were being carried out with the serum in children and adolescents until more evidence about side effects is available.
EMA contradicts its chief of vaccines: says there is still no “clear” link between thrombi and AstraZeneca doses
According to ‘ The Wall Street Journal ‘, the decision to pause the pediatric trial has been taken as a precaution in the face of cases of thrombosis in vaccinated adults from different European countries.
The study, which began in mid-February, aims to test the vaccine in about 200 children and adolescents between the ages of six and 17. Although, they say, they have not detected any significant problems in the tests so far, they prefer to stop the study until there is more information about the possible relationship between the vaccine and the effects of clots.
This happens the same day that the head of the European Medicines Agency (EMA) vaccine strategy, Marco Cavaleri, has assured that there is a “clear” link between vaccination with AstraZeneca and the cases of thrombi. “In my opinion we can now say that it is clear that there is an association (of thrombi) with the vaccine. However, we still do not know what causes this reaction,” he told the Italian newspaper “Il Messaggero”.
For its part, the EMA has already announced that it will appear “late on Wednesday” to issue an opinion on the matter, although it anticipates that they still do not know the causes of these reactions.
The World Health Organization ( WHO ) has also spoken out about it and insisted that “for now” there is no evidence that it is the British vaccine that causes these thrombotic events.